Iván J. Suñer
About
In The Last Decade
Iván J. Suñer
33 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Ophthalmology 1.8k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Molecular Biology 354
- Epidemiology 149
- Neurology 127
Countries citing papers authored by Iván J. Suñer
This map shows the geographic impact of Iván J. Suñer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iván J. Suñer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iván J. Suñer more than expected).
Fields of papers citing papers by Iván J. Suñer
This network shows the impact of papers produced by Iván J. Suñer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iván J. Suñer. The network helps show where Iván J. Suñer may publish in the future.
Co-authorship network of co-authors of Iván J. Suñer
This figure shows the co-authorship network connecting the top 25 collaborators of Iván J. Suñer. A scholar is included among the top collaborators of Iván J. Suñer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iván J. Suñer. Iván J. Suñer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 10 | |
| 4 | 1 | |
| 5 | 28 | |
| 6 | 19 | |
| 7 | Content validity of the NEI VFQ-25 in patients with geographic atrophy | 1 |
| 8 | 109 | |
| 9 | 9 | |
| 10 | 18 | |
| 11 | 48 | |
| 12 | Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration breakdown → | 407 |
| 13 | 26 | |
| 14 | HARBOR Study: One-Year Results of Efficacy and Safety of 2.0 mg versus 0.5 mg Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration | 4 |
| 15 | 126 | |
| 16 | 93 | |
| 17 | Ranibizumab Improves Patient-Reported Near and Distance Vision Activities in Patients With Macular Edema Following Retinal Vein Occlusion | 1 |
| 18 | Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results From MARINA | 3 |
| 19 | 46 | |
| 20 | 119 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.